Amid lay­off fears, As­traZeneca stakes a ‘For Sale’ sign on US cam­pus

Af­ter culling work­ers in Boston and Mary­land, As­traZeneca is con­sid­er­ing its op­tions for its US head­quar­ters cam­pus in Delaware. The lo­cal pa­pers have been re­port­ing that the phar­ma gi­ant has de­cid­ed to put its HQ up for sale, but is look­ing for a deal to lease it back.

Back in May the com­pa­ny trig­gered fears of a loom­ing re­struc­tur­ing that would like­ly trig­ger job cuts on the 30-acre site af­ter a spokesper­son con­firmed that it was con­sid­er­ing sell­ing the site and mov­ing to a new lo­ca­tion in the state.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.